Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This trial is designed to investigate the safety, tolerability and the effectiveness when
OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with
metastatic colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Genentech, Inc. Hoffmann-La Roche Massachusetts General Hospital OSI Pharmaceuticals Sanofi-Synthelabo